The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
Inovio’s pipeline is most active in early-stage drug development
INO-4800 is Inovio’s COVID-19 vaccine
Funding from different sources for INO-4800
This 29-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.
Inovio Pharmaceuticals Inc.
Table of Contents
1 Executive Summary
2 Company Overview
2.1 Key Stats
2.2 SWOT Analysis
2.3 Sales Forecast Overview
3 Regional Analysis
3.1 COVID-19 Spread vs. Location of Inovio Pharmaceuticals Inc. Trials
3.2 COVID-19 vs. Non-COVID-19 Trials
4 Reaction to COVID-19
4.2 Insight’s Exclusive Intel: Inovio Pharmaceuticals
4.3 Global Analyst Consensus Sales Forecast
4.4 Upcoming Events
4.5 Recent Deal Activity
5 Key Findings
6.2 About GlobalData
Tel +44 (0) 20 7947 2960
Personal and transaction information are kept safe from unauthorised use.